Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tsuneaki Hida is active.

Publication


Featured researches published by Tsuneaki Hida.


Tetrahedron Letters | 1986

Structure of lactivicin, an antibiotic having a new nucleus and similar biological activities to β-lactam antibiotics

Setsuo Harada; Shigetoshi Tsubotani; Tsuneaki Hida; Hideo Ono; Hisayoshi Okazaki

Abstract The structure of a new antibiotic, lactivicin, was determined to be [4S]-2-(4-acetylamino-3-oxo-2-isoxazolidinyl)-5-oxo-tetrahydrofuran-2-carboxylic acid.


International Journal of Immunopharmacology | 1994

Augmentation of host defense mechanisms against tumor by sperabillin polymers, new basic peptidyl biopolymers, in mice.

Masayuki Takizawa; Tsuneaki Hida; Setsuo Harada; Seiichi Tanida

Sperabillin polymers, which have been shown recently to have antitumor activity, are new basic peptidyl polymers composed of a pseudo-peptide antibiotic, sperabillin A. The polymers, HP-2 (MW 9990), AP-2 (MW 20,100) and AB-2 (MW 35,000), were found to potently activate murine peritoneal macrophages. The phagocytosis-dependent respiratory burst and Fc gamma receptor expression of peritoneal macrophages from C57BL/6 mice were enhanced after in vitro cultivation with these polymers. When HP-2, a representative of these polymers, was intraperitoneally injected into mice, the number of peritoneal exudate cells increased and phagocytosis-dependent respiratory burst and class II (I-A) antigen expression of peritoneal macrophages were augmented. These macrophages showed strong inhibitory activity against the growth of murine tumor cell lines such as EL4 lymphoma and B16 melanoma. Nitrogen oxide, tumor necrosis factor (TNF) and interleukin 1 (IL-1) might be required for this inhibitory activity. Moreover, in mice treated with HP-2, splenocyte counts also increased and non-specific killer activity of the splenocytes was augmented. These results indicate that sperabillin polymers are new macrophage activators.


The Journal of Antibiotics | 1985

Formadicins, new monocyclic .BETA.-lactam antibiotics of bacterial origin. II. Isolation, characterization and structures.

Tsuneaki Hida; Shigetoshi Tsubotani; Nozomi Katayama; Hisayoshi Okazaki; Setsuo Harada


The Journal of Antibiotics | 1984

Cephabacins, new cephem antibiotics of bacterial origin. III. Structural determination.

Shigetoshi Tsubotani; Tsuneaki Hida; Fumiko Kasahara; Yoshikazu Wada; Setsuo Harada


The Journal of Antibiotics | 2000

TAN-1813, a Novel Ras-Farnesyltransferase Inhibitor Produced by Phoma sp. : Taxonomy, Fermentation, Isolation and Biological Activities In Vitro and In Vivo

Takafumi Ishii; Kozo Hayashi; Tsuneaki Hida; Yasuharu Yamamoto; Yukimasa Nozaki


The Journal of Antibiotics | 1993

TAN-1120, A NEW ANTHRACYCLINE WITH POTENT ANGIOSTATIC ACTIVITY

Yukimasa Nozaki; Tsuneaki Hida; Sffigemi Iinuma; Takafumi Ishii; Katsuichi Sudo; Masayuki Muroi; Tsuneo Kanamaru


The Journal of Antibiotics | 1985

Cephabacin M1-6, new 7-methoxycephem antibiotics of bacterial origin. II. Isolation, characterization and structural determination.

Shigetoshi Tsubotani; Tsuneaki Hida; Hideo Ono; Setsuo Harada


The Journal of Antibiotics | 1995

TAN-1323 C and D, new concanamycin-group antibiotics ; detection of the angiostatic activity with a wide range of macrolide antibiotics

Takafumi Ishii; Tsuneaki Hida; Shigemi Iinuma; Masayuki Muroi; Yukimasa Nozaki


The Journal of Antibiotics | 1995

Synthesis and biological activities of TAN-1511 analogues.

Tsuneaki Hida; Kozo Hayashi; Koichi Yukishige; Seiichi Tanida; Noriaki Kawamura; Setsuo Harada


The Journal of Antibiotics | 1994

Structures of dnacin A1 and B1, new naphthyridinomycin-type antitumor antibiotics.

Tsuneaki Hida; Masayuki Muroi; Seiichi Tanida; Setsuo Harada

Collaboration


Dive into the Tsuneaki Hida's collaboration.

Top Co-Authors

Avatar

Setsuo Harada

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Seiichi Tanida

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takafumi Ishii

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shigetoshi Tsubotani

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yukimasa Nozaki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Masayuki Muroi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Koichi Yukishige

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Koichiro Ootsu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mitsuhiro Wakimasu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Tsuneo Kanamaru

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge